Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Synthena AG has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions involve 2 distinct examiners but are both located within 1 distinct art unit. This indicates that while the technical subject matter is consistent enough for 1 art unit, it is being reviewed by 2 different individuals. For the practitioner, this requires managing 2 separate examination styles while maintaining a consistent technical narrative within the same art unit.
ZARA, JANE J is the busiest examiner, with 1 pending office action. Given the total of 2 pending office actions, this examiner is responsible for a portion of the active workload. The 2 examiners each manage 1 action, resulting in a distributed review process within the single art unit. This distribution means the company's prosecution outcomes are not dependent on a single individual but are instead influenced by the findings of 2 different examiners. Strategically, the legal team must monitor how ZARA, JANE J and the other examiner interpret the shared technical context of the 1 art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| MCKILLOP, JOHN CHARLES | 1 | 61.4% | +40.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18524916 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | ZARA, JANE J | — |
| 17206038 | Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof | MCKILLOP, JOHN CHARLES | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18524916 | MODIFIED OLIGOMERIC COMPOUNDS COMPRISING TRICYCLO-DNA NUCLEOSIDES AND USES THEREOF | ZARA, JANE J | 1637 | §112DP | Non-Final OA | — | Pending | Nov 30, 2023 |
| 17206038 | Mixed Tricyclo-DNA, 2'-Modified RNA Oligonucleotide Compositions and Uses Thereof | MCKILLOP, JOHN CHARLES | 1637 | §103§112DP | Final Rejection | — | Pending | Mar 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSynthena AG has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Jane J Zara has the most, with 1 of Synthena AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
